DNX/GenPharm cross-licensing agreement
Executive Summary
Covers two fundamental technologies for the development of transgenic animals, DNX' microinjection technology and GenPharm's homologous recombination technology. The two companies will pay annual license fees as well as royalties on commercial sales of transgenic animals, recombinant biopharmaceuticals and other products produced via transgenic animals.